Vitamin D blood test: 25(OH)D ranges, low and high results

There is no universal optimal level. The US National Academies framework considers below 12 ng/mL (30 nmol/L) a risk of deficiency, 12 to below 20 ng/mL (30 to below 50 nmol/L) generally inadequate, and at least 20 ng/mL (50 nmol/L) generally adequate for most healthy people. Laboratories and regional guidance can use different categories, so read the range and clinical purpose on the original report.

Yes. Multiply ng/mL by 2.5 to convert to nmol/L, so 30 ng/mL equals 75 nmol/L. Divide nmol/L by 2.5 to convert back.

They come from different frameworks and purposes. The National Academies says 20 ng/mL (50 nmol/L) is generally adequate for most healthy people, while some laboratories and older clinical guidance use 30 ng/mL. The 2024 Endocrine Society guideline did not establish one outcome-specific sufficiency target for healthy people.

Total serum 25-hydroxyvitamin D, or 25(OH)D, is the usual status test. It includes 25(OH)D₂ and 25(OH)D₃. The active hormone 1,25-dihydroxyvitamin D is tightly regulated and can stay normal until deficiency is severe, so it is used for narrower clinical questions rather than routine status checking.

Fasting is not usually required for 25(OH)D alone. Follow the instructions for every test ordered in the same blood draw, and do not stop prescribed medicines or supplements unless the ordering clinician tells you to.

No. The 2024 Endocrine Society guideline suggests against routine 25(OH)D testing in generally healthy people without an established reason, and the US Preventive Services Task Force found the evidence insufficient to determine whether screening asymptomatic adults has more benefit than harm. Testing is more useful when symptoms, bone disease, malabsorption, kidney or liver disease, medicines, toxicity concern or another clinical decision makes the result actionable.

Possible contributors include limited ultraviolet B exposure, low intake, darker skin, older age, obesity, fat malabsorption, bariatric surgery, liver or kidney disease and medicines that affect vitamin D metabolism. A result does not identify which cause applies.

Yes. Mildly low results often cause no specific symptoms. Bone pain, muscle weakness, fractures or low calcium can occur with more important deficiency, but these problems have other causes and cannot reveal a vitamin D number by themselves.

Yes. 25(OH)D often falls after periods with less ultraviolet B exposure and rises after sunnier months. Latitude, time outdoors, clothing, skin pigmentation and supplement use change the size of that seasonal effect. Compare trends at similar times of year when practical.

Yes. Immunoassays and liquid chromatography–tandem mass spectrometry can differ, and measurements can be affected by how 25(OH)D₂ and 25(OH)D₃ are detected. Standardization programs reduce this problem, but an unexpected change is easiest to assess with the same laboratory and method.

It changes over weeks rather than hours, and the response is nonlinear. Baseline level, dose, duration, body size, absorption and adherence all matter. A clinician should choose any repeat interval around the reason for treatment rather than using an internet schedule.

Possibilities include an inconsistent or insufficient regimen, overlapping products being counted incorrectly, reduced absorption, obesity, medicines that alter vitamin D metabolism, severe liver or kidney disease, seasonal change, or a laboratory-method difference. A repeat result should first be checked against the exact product, dose, duration, adherence, assay and clinical reason rather than automatically escalating the dose.

Not automatically. The NIH vitamin D fact sheet and the 2024 Endocrine Society prevention guideline used for this guide do not tell everyone taking vitamin D to add vitamin K2 or magnesium. That does not mean these nutrients never matter: a confirmed deficiency or another clinical indication should be assessed separately. A supplement stack is not a substitute for identifying why 25(OH)D is low.

Confirmed deficiency is commonly treated, but the product, dose and follow-up depend on the level, symptoms, calcium, pregnancy, age, kidney function, absorption and cause. Do not use a high-dose regimen or combine products from a single online threshold.

Both can raise 25(OH)D and treat deficiency. Evidence summarized by the NIH indicates that vitamin D₃ often raises and maintains 25(OH)D more than vitamin D₂, but formulation, dose, dietary preferences, access and the clinical plan still matter.

Yes. Excess supplement intake can cause hypercalcemia, which may lead to nausea, weakness, thirst, frequent urination, kidney stones, kidney injury or abnormal heart rhythm. Toxicity is almost always related to excessive intake rather than ordinary sunlight exposure.

There is no single number that diagnoses toxicity. The NIH notes that toxicity typically involves marked 25(OH)D elevation, often above 150 ng/mL (375 nmol/L), together with hypercalcemia. Laboratory alert boundaries can differ. A high result must be read with calcium, symptoms, supplements and kidney function.

Not automatically. A 2026 systematic review of 69 randomized trials found little or no fracture or fall prevention benefit from vitamin D for adults outside osteoporosis-drug treatment, consistent with the large VITAL fracture trial. These findings do not argue against treating rickets, osteomalacia, established deficiency or following a condition-specific bone-health plan.